AI Article Synopsis
- The study investigates whether switching kidney transplant recipients (KTR) from cyclosporine A (CyA) to tacrolimus (Tac) can slow down chronic allograft nephropathy (CAN) progression.
- After a year, the Tac group showed decreased serum creatinine levels and lower antihypertensive scores compared to the CyA group, indicating improved kidney function and lower blood pressure.
- The findings suggest that using Tac instead of CyA can lead to better long-term health outcomes for kidney transplants by potentially enhancing graft survival.
Article Abstract
Background: Chronic allograft nephropathy (CAN) is a multifactorial process with immunologic and nonimmunologic factors. Because tacrolimus (Tac) has been ascribed a beneficial effect on some of these factors when compared to cyclosporine A (CyA), a randomized controlled trial was conducted to investigate whether conversion from CyA to Tac can ameliorate the progression of renal dysfunction in kidney transplant recipients (KTR) with CAN.
Methods: Of the 46 patients with biopsy-proven CAN enrolled, 24 were converted from CyA to Tac, whereas 22 patients were maintained on CyA. Serum creatinine (SCrea), lipid profiles and an antihypertensive score (AHS) were determined after 3, 6 and 12 months. AHS is based on the total number and dosages of antihypertensive medications used. SCrea and AHS were additionally evaluated at 36 months.
Results: SCrea was decreased in the Tac group (Tac(baseline): 297 +/- 67 micromol/L; Tac(6): 261+/- 70 micromol/L, P < 0.001; Tac(12): 254 +/- 55 micromol/L, P < 0.001; Tac(36): 255 +/- 78 micromol/L, P = 0.235), whereas a significant increase of SCrea was detected in the CyA group (CyA(baseline): 279 +/- 77 micromol/L, CyA(12): 333 +/- 98 micromol/L, P < 0.001; CyA(36): 317 +/- 89 micromol/L, P < 0.001). Compared to CyA therapy, SCrea in the Tac group declined after 12 and 36 months (P = 0.011 and 0.048, respectively) as well as AHS (Tac(12): 59 +/- 13, CyA(12): 83 +/- 14, P < 0.001; Tac(36): 60 +/- 12, CyA(36): 84 +/- 14, P < 0.001). LDL cholesterol was lower in the Tac group after 12 months (Tac(12): 2.5 +/- 0.5 mmol/L, CyA(12): 3.5 +/- 0.6 mmol/L, P < 0.001).
Conclusion: Conversion from CyA to Tac in KTR with CAN improves allograft function, lowers blood pressure, and reduces LDL cholesterol. This superior profile may translate into improved long-term graft survival.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.tp.0000220480.84449.71 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Rare Case of Neuronal Ceroid Lipofuscinosis-Type 1 (NCL-1) with Vitamin D-Dependent Rickets-Type 1 (VDDR-1), Complex 1 Mitochondrial Deficiency, and Mixed Variant-Checkerboard and Phylloid Type of Pigmentary Mosaicism.
J Pediatr Genet
December 2024
Centre for Human Genetics, Bengaluru, Karnataka, India.
Neuronal ceroid lipofuscinosis-type 1 (NCL-1) is a neurodegenerative lysosomal storage disorder. Vitamin D-dependent rickets type 1 (VDDR-1) is a rare cause of refractory rickets. Here, we report an unusual association of NCL-1 with VDDR-1.
View Article and Find Full Text PDFPosterior urethral valves: Clinical audits of presentation, diagnostic and therapeutic intervention in a nigerian teaching hospital.
Int Urol Nephrol
October 2024
Urology Division, Department of Surgery, College of Health Sciences, Osun State University and Uniosun Teaching Hospital, Osogbo, Nigeria.
Purpose: We described our experience in the management of PUV at UNIOSUN Teaching Hospital, Osogbo, Osun State.
Methods: This was a retrospective analysis of patients with diagnosis of PUV carried out over a 4 year period (2019-2023). Demographic characteristics, clinical presentation, diagnosis and mode of therapeutic interventions were the variables analysed.
Background: Pre-eclampsia is a syndrome that chiefly includes the development of new-onset hypertension and proteinuria after 20 weeks of pregnancy. Pre-eclampsia is one of the major causes of mortality and morbidity in Nepal. Hyperhomocysteinemia may be a cause of the endothelial dysfunction provoked by oxidative stress in pre-eclampsia.
View Article and Find Full Text PDFFirst successful outcomes of pegvaliase (PALYNZIQ) in children.
BMC Med Genomics
March 2024
College of Medicine, King Saud bin Abdulaziz University for Health Sciences (KSAU-HS), King Abdulaziz Medical City, Ministry of National Guard Health Affairs (MNG-HA), Riyadh, Saudi Arabia.
Article Synopsis
- - PKU is a genetic disorder caused by a deficiency in the enzyme phenylalanine hydroxylase, leading to high levels of phenylalanine in the blood; pegvaliase (PALYNZIQ®) has been approved for treating adults with uncontrolled Phe levels above 600 micromol/L, but its effects on children under 16 are not well-studied.
- - A case study of a 12-year-old Saudi girl who received pegvaliase therapy showed significant improvement in her blood Phe levels after six months, allowing her to maintain a normal diet without restrictions while keeping her Phe levels stable.
- - The findings suggest pegvaliase may be safe and effective for children with PKU, highlighting
Raised Maternal Homocysteine Levels in Antenatal Women at 10 to 14 Weeks of Gestation and Placenta-Mediated Complications: A Cohort Study.
Cureus
June 2023
Department of Obstetrics and Gynaecology, NKP Salve Institute of Medical Sciences and Research Centre, Nagpur, Maharashtra, IND.
Background Placenta-mediated complications, such as preeclampsia, placental abruption, and fetal growth restriction, can indeed lead to significant maternal and perinatal morbidity and mortality. Early detection and management of these conditions are crucial to ensuring optimal outcomes for both the mother and baby. However, there have been inconsistent correlations found between maternal homocysteine levels and placenta-related problems in various studies.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!